BDA-366 is primarily researched for its potential applications in cancer therapy. It functions as a BH4 domain antagonist, specifically targeting Bcl-2, a protein that plays a critical role in regulating cell death. By inhibiting Bcl-2, BDA-366 promotes apoptosis in cancer cells, making it a promising candidate for treating cancers that overexpress Bcl-2, such as certain types of leukemia and lymphoma. Its ability to selectively induce cell death in malignant cells while sparing normal cells highlights its potential as a targeted therapeutic agent. Ongoing studies are focused on optimizing its efficacy and safety profile for clinical use.